Product Pipeline: Pharmaceutical Pipeline for New Drugs | Pfizer

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.

Discovery Projects
Phase 1
29
Phase 2
40
Phase 3
23
Registration
8
Total100

Current Projects
Discontinued Projects

Compound Name	Indication	Phase	Submission Type	Compound Type
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti-PD-1 Go to clinical trial	Non-Muscle-Invasive Bladder Cancer (Biologic)	Phase 3	New Molecular Entity	Biologic
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor Go to clinical trial	Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer	Phase 3	Product Enhancement	Small Molecule
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor	Combo w/ Xtandi (enzalutamide) for DDR-deficient Metastatic Castration Sensitive Prostate Cancer Project advanced	Phase 3	Product Enhancement	Small Molecule
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor Go to clinical trial	Non-metastatic High-Risk Castration Sensitive Prostate Cancer	Phase 3	Product Enhancement	Small Molecule
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor and anti PD-1	BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma	Phase 3	Product Enhancement	Small Molecule
Braftovi (encorafinib) + Erbitux® (cetuximab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor and anti EGFR Go to clinical trial	1st line BRAF-mutant Metastatic Colorectal Cancer	Phase 3	Product Enhancement	Small Molecule
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1	Combo w/CMP-001 for Head and Neck Cancer (Biologic)	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1	Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic)	Phase 2	Product Enhancement	Biologic
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1	Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic)	Phase 2	Product Enhancement	Biologic
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor	1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer	Phase 2	Product Enhancement	Small Molecule
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor	2nd Line Metastatic Castration-Resistant Prostate Cancer	Phase 2	Product Enhancement	Small Molecule
Elranatamab Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: BCMA-CD3 Bispecific Antibody	Multiple Myeloma Triple-Class Refractory (Biologic)	Phase 2	New Molecular Entity	Biologic
ARV-471 Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: ER-targeting PROTAC® protein degrader	ER+/HER2- Metastatic Breast Cancer Project advanced	Phase 2	New Molecular Entity	Small Molecule
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity	Cancer (Biologic)	Phase 1	New Molecular Entity	Biologic
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 Inhibitor	Cancer	Phase 1	New Molecular Entity	Small Molecule
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 Inhibitor	Breast Cancer Metastatic	Phase 1	New Molecular Entity	Small Molecule
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor	Solid Tumors	Phase 1	New Molecular Entity	Small Molecule
PF-06940434 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Integrin alpha-V/beta-8 Antagonist	Solid Tumors (Biologic)	Phase 1	New Molecular Entity	Biologic